MD[ Merck Investigator]Bladder cancer is a common and deadly disease

William Y. MD[ Merck Investigator]Bladder cancer is a common and deadly disease, the fourth most common cancer in men. Kim is conducting a clinical trial investigating the efficacy of erlotinib / Tarceva, an EGFR inhibitor drug, bladder cancer . Its aim is predictors of predictors of patient response to erlotinib and other EGFR inhibitors, and to determine how best to coordinate EGFR inhibition with chemotherapy. These studies should have direct clinical implications for this deadly disease, so the treatment of patients most likely to benefit while minimizing unnecessary toxicity in which hardly respond. Kim works under the guidance of Charles M. At the University of North Carolina, Chapel Hill, North Carolina. Ryan Miller, PhD[ Genentech Investigator].

The Clinical Investigator Award program aims particularly, the lack of doctors may translate scientific discovery into new breakthroughs for cancer patients. In partnerships with industry sponsors , the Damon Runyon Cancer Research Foundation has committed more than $ 32,000, supports the careers of 48 physician – scientists in the United States since 2000.

The survey, sponsored by pharmaceutical company UCB points out that RA had a key factor in a quarter of distinctions from women to the disease, and that 53 % of single woman replied to the questionnaire responded to the survey notified their RA being additional obstacle in partners. – My patients the feeling that her excluding complaints meant carried members of the family and close colleagues , which affects their social relationships essential good, said Roy Fleischmann, 1, of Medicine at University of Texas Southwestern Medical Center in Dallas. Many prefer to to hide their degree of discomfort to others, because it too difficult to attempt to in order to explain pain and reduced ability feel and functional for those. Do not have these restriction .